Powering enzyme engineering
Our proprietary CodeEvolver® technology platform has the power to revolutionize enzyme performance, tailoring it for specific applications and processes. Leveraging advanced machine-learning tools with complex molecular, cellular, and bioanalytical workflows, we design, screen, and analyze libraries of thousands of enzyme variants in high throughput, sequencing each variant and correlating its sequence with its performance.
Content-rich libraries are screened under real-world conditions that yield dense datasets, with multiple parameters optimized in parallel. The resulting evolved variants often have a combination of enhanced properties, such as increased activity, specificity, stability, and expression. These enhanced properties translate into improved technical performance in the intended application and generate a return on investment in commercial settings.
The CodeEvolver® technology platform enables the discovery of biocatalysts for the manufacture of small molecule pharmaceuticals, with greatly improved traits including activity, selectivity, and stability. When combined into consecutive enzymatic conversions, the biocatalytic cascades can accomplish difficult chemistry under mild reaction conditions, with minimal waste generation and attractive economics. We currently have 18 commercial API programs, a further 18 in Phase II/III studies, three platform licenses, and over 50 programs in research and early clinical phases.
Using our CodeEvolver® technology platform, we engineer enzymes as potential oral drugs that are highly stable to the harsh conditions of the gastrointestinal (GI) tract. In our partnership with Nestlé Health Science there are four enzymes in development. For gene therapy, we evolve capsids for more effective targeting and optimize the expression, stability, and potency of the transgene product being delivered. There are four engineered transgene projects underway with Takeda.
Enzymes play a critical role in life science workflows. Using the CodeEvolver® technology platform, we have developed a novel engineered DNA ligase for NGS with superior ligation efficiency, and an RNA polymerase to produce quality mRNA at commercial scale. The CodeEvolver® technology platform underpins the key innovations behind the new Enzyme-Catalyzed Oligonucleotide Synthesis ECO SynthesisTM technology, which promises to disrupt existing phosphoramidite-based processes.